IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Pa	itent Applica	tion of:						
Ji-Sick	HWANG							
Applica	tion No.: TC	BE ASSIGNED	Group Art Unit: TO BE ASSIGNED					
Filed:	October 1, 2	003	Examiner:					
For:	ICE MAKER							
		INFORMATION DISCLOS	SURE STATEMENT					
P.O. Bo	ssioner for P ox 1450 dria, VA 223							
Sir:								
provide subject	d certain info U.S. patent	ormation which the Examiner ma	ovisions of 37 CFR § 1.56, there is hereby ay consider material to the examination of the the Examiner make this information of record bject application.					
1.	Enclosures accompanying this Information Disclosure Statement are:							
	1a.	application or a PCT Internation English language translation (A language publication. Explanations of Relevancy of F providing a concise explanation List of Copending Applications	Abstract Only) attached to each non-English References (ATTACHMENT 1(e), hereto) for n of each non-English publication.					
2. 🛛	This Infor	mation Disclosure Statement is						
	2a. ☐ 2b. ☐ 2c. ☒ 2d. ☐	Continued Prosecution Applica Within three months of the dat § 1.491 in an international app Before the mailing of a first Off	g date of a national application other than a ation under § 1.53(d); e of entry of the national stage as set forth in lication. Tice Action on the merits; or Tice Action after the filing of a Request for					

Serial No.: TO BE ASSIGNED

3.	Specified Action ur	rmation Disclosure Statement is filed under 37 CFR § 1.97(c) after the period in paragraph 2 above but before the mailing date of any of a Final Office oder § 1.113, a Notice of Allowance under § 1.311 or an action that otherwise rosecution in the application, AND					
		(Check either Item 3a or 3b; Item 3b to be checked if					
	3a. 🗌 3b. 🗍	any reference known for more than 3 months) The §1.97(e) Statement in Item 5 below is applicable; OR The \$180.00 fee set forth in 37 C.F.R. §1.17(p) is: enclosed.					
		to be charged to Deposit Account No. 19-3935.					
4.	This Inforspecified 4a. 4b.	rmation Disclosure Statement is filed under 37 CFR §1.97(d) after the period in paragraph 3 above, but on or before payment of the Issue Fee, AND The § 1.97(e) Statement in Item 5 below is applicable; AND The \$180.00 fee set forth in 37 C.F.R. §1.17(p) is: enclosed.					
		to be charged to Deposit Account No. 19-3935.					
5.	Statement under § 1.97(e) (applicable if Item 3a or Item 4 is checked)						
	c- 🗆	(Check either Item 5a or 5b)					
	5a. 🗌	In accordance with 37 CFR § 1.97(e)(1), it is stated that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.					
	5b.	In accordance with 37 CFR § 1.97(e)(2), it is stated that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known by any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.					
6.	This is a continuation/divisional/continuation-in-part application under 37 CFR § 1.53(b).						
		(Check appropriate Items 6a and/or 6b)					
	6a. 🗌	Copies of the publications listed on the attached Form PTO-1449 which were previously cited in prior application Serial No, filed on, and which is relied on for an earlier effective filing date for the subject application under 35 U.S.C. § 120, have been omitted pursuant to 37 CFR					
	6b. 🗌	§ 1.98(d). Copies of the publications listed on the attached Form PTO-1449 which were not previously cited in prior application Serial No, filed on, and which is relied on for an earlier effective filing date for the subject application under 35 U.S.C. § 120, are provided herewith					

Serial No.: TO BE ASSIGNED

7.		This is a Continu	a continuation/divisional application under 37 CFR § 1.53(d) or Request for ed Examination under 37 CFR 1.114.
			(Check either Item 7a or 7b)
		7a. 🗍 7b. 🗍	The Issue Fee has not been paid. A Petition to Withdraw from issue under 37 CFR §1.313(c) is filed concurrently herewith or has been granted. A continuation application under 37 CFR § 1.53(d) or Request for Continued Examination under 37 CFR 1.114, after payment of the Issue Fee is proper in accordance with 37 CFR § 1.53(d)(1)(ii) or 37 CFR 1.114(a), respectively.
8.		This is a	Supplemental Information Disclosure Statement.
			(Check either Item 8a or 8b)
		8a. 🗌	This Supplemental Information Disclosure Statement under 37 CFR § 1.97(f) supplements the Information Disclosure Statement filed on A bona fide attempt was made to comply with 37 CFR § 1.98, but inadverten omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental IDS can be considered as if properly filed on
		8b. 🗌	This Supplemental Information Disclosure Statement is timely filed within one (1) month of the Notice under 37 CFR § 1.97 and 1.98, mailed (MPEP 609 C(1), Form ¶ 6.49, Rev. 1, Feb. 2000, pp. 600-107)
9.	⊠ Ir u	n accorda	ince with 37 CFR § 1.98, a concise explanation of what is presently d to be the relevance of each non-English language publication is:
			(Check appropriate Items 9a, 9b, 9c and/or 9d)
		9a. 🗌	satisfied because all non-English language publications were cited on the enclosed English language copy of the PCT International Search Report or the search report from a counterpart foreign application indicating the degree of relevance found by the foreign office. (See U.S. Patent & Trademark Office's authorization in the Federal Register, Vol. 57, No. 12, January 17, 1992, at page 2031 (Reply to Comment 68).)
		9b. □ 9c. ⊠	set forth in the application. satisfied because an English language translation (Abstract Only) is
		9d. 🗌	attached to each non-English language publication. enclosed as Attachment 1(e), hereto.
10.	be tha	, material an search	on is made that the information cited in this Statement is, or is considered to to patentability nor a representation that a search has been made (other report(s) from a counterpart foreign application or a PCT International ort, if submitted herewith). 37 CFR §§ 1.97(g) and (h).

Serial No.: TO BE ASSIGNED

11. The Commissioner is authorized to credit any overpayment or charge any additional fee required under 37 CFR § 1.17 for this Information Disclosure Statement and/or Petition to Deposit Account No. 19-3935.

By:

Respectfully submitted,

STAAS & HALSEY LLP

Dated: /0///02

1201 New York Avenue, N.W.

Suite 700

Washington, D.C. 20005 Telephone: (202) 434-1500 Facsimile: (202) 434-1501

FORM PTO-1449 U.S. DEPARTMEN PATENT AND TRA LIST OF REFERENCES CITED BY					1594.1271				Sheet 1 of 1 APPLICATION NO. TO BE ASSIGNED		
				FIRST NAMED INVENTOR							
LIST OF	IXLI	LINENCES (וובט פז	APPLICANT	Ji-Sick HV						
(Use several sheets if necessary)				FILING DATE				GROUP ART UNIT			
				October 1, 2003			TO BE ASSIGNED				
			U.S. P	ATENT DOCUMEN	NTS						
EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME		CLASS		SUB- CLASS		FILING DATE	
	AA				· · · · · · · · · · · · · · · · · · ·						
	AB					<u> </u>					
	AC										
	AD										
··· .	AE							,			
	AF										
	<u>l</u>		FOREIGN	N PATENT DOCUM	ENTO						
		DOCUMENT	POREIGI	TAIENT DOCON	IENIS			JB- TRAN ASS YES		NSLATION S NO	
!		NO.	DATE	COUNTRY	CL						
	AG	200-88414	03/31/00	Japan					Abstr	act	
	АН										
	Al										
	AJ										
			<u> </u>	<u> </u>					<u> </u>	1	
HER REF	AM	CES (Including A	<u>Nuthor, Title,</u>	Date, Pertinent Pa	ges, Etc.)						
	A N I										
	AN										
XAMINER				DATE C	ONSIDERE	D					